Prosecution Insights
Prosecution Insights
Tech Center 3900 • Art Units: 1600 1651 1653 3991
This examiner grants 31% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18414545 | THERAPEUTIC AGENT FOR MALIGNANT TUMORS EXPRESSING MHC CLASS II | Non-Final OA | Juntendo Educational Foundation |
| 18547471 | ANTIBODIES, FRAGMENTS OR DERIVATIVES SPECIFICALLY BINDING TO A PROTEIN ANTIGEN CAPABLE OF BINDING TO NUCLEIC ACIDS AND USES OF SAME | Non-Final OA | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES |
| 18774363 | NANOEMULSION COMPOSITIONS OF TAXOID DRUGS, AND METHODS FOR THE USE THEREOF TO TARGET CANCER CELLS AND CANCER STEM CELLS | Final Rejection | Northeastern University |
| 18131746 | TOPICAL SKIN CARE FORMULATIONS COMPRISING PLANT EXTRACTS | Non-Final OA | MARY KAY INC. |
| 18272168 | CD64 CHIMERIC RECEPTOR AND USES THEREOF | Non-Final OA | CONSIGLIO NAZIONALE DELLE RICERCHE |
| 18264191 | THERAPEUTIC COMBINATION AND USE THEREOF | Non-Final OA | Akeso Pharmaceuticals, Inc. |
| 18355451 | TAFA4 Compounds and Uses Thereof for Treating Pain | Non-Final OA | Universite D'Aix-Marseille |
| 18223979 | SYSTEM AND METHOD FOR AUTOMATED DETECTION AND MONITORING OF DYSPLASIA AND ADMINISTRATION OF IMMUNOTHERAPY AND CHEMOTHERAPY | Non-Final OA | VISIONGATE, INC. |
| 18031479 | METHODS OF TREATING DIFFUSE LARGE B-CELL LYMPHOMA | Non-Final OA | IMMUNOVACCINE TECHNOLOGIES INC. |
| 18130112 | ACTIVATABLE IL2 COMPOSITION AND METHODS OF USE | Non-Final OA | Immune Targeting, Inc. |
| 18102588 | AGENTS USEFUL IN TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | Final Rejection | Universite de Mons |
| 17928206 | TESTICULAR FUNCTION-IMPROVING AGENT AND TESTICULAR FUNCTION-IMPROVING METHOD | Non-Final OA | DEXON PHARMACEUTICALS INC. |
| 17984985 | ANTI-SIALYL TN CHIMERIC ANTIGEN RECEPTORS | Non-Final OA | Helixmith Co., Ltd |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy